Molecular Basis of Drug Resistance in Aurora Kinases

Chemistry and Biology

Volumn 15, Issue 6, 2008, Pages 552-562

  Girdler, Fiona ^a   Sessa, Fabio ^b   Patercoli, Simona ^b   Villa, Fabrizio ^b   Musacchio, Andrea ^b,c   Taylor, Stephen ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^c ISTITUTO ITALIANO DI TECNOLOGIA   (Italy)

Author keywords

CHEMBIO; SIGNALING

Indexed keywords

4 (4 (N BENZOYLAMINO)ANILINO) 6 METHOXY 7 (3 (1 MORPHOLINO)PROPOXY)QUINAZOLINE; 4-(4-(N-BENZOYLAMINO)ANILINO)-6-METHOXY-7-(3-(1-MORPHOLINO)PROPOXY)QUINAZOLINE; AURORA KINASE; BENZAMIDE DERIVATIVE; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; QUINAZOLINE DERIVATIVE;

ALLELE; ARTICLE; CELL CYCLE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; DRUG RESISTANCE; GENETICS; HUMAN; PHOSPHORYLATION; POINT MUTATION; TUMOR CELL LINE;

ALLELES; BENZAMIDES; CELL CYCLE; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; HUMANS; MODELS, MOLECULAR; PHOSPHORYLATION; POINT MUTATION; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; QUINAZOLINES;

PYRONIA TITHONUS;

EID: 44949157910     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chembiol.2008.04.013     Document Type: Article

References (40)

1. Barr A.R., and Gergely F. Aurora-A: the maker and breaker of spindle poles. J. Cell Sci. 120 (2007) 2987-2996
2. Burgess M.R., Skaggs B.J., Shah N.P., Lee F.Y., and Sawyers C.L. Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance. Proc. Natl. Acad. Sci. USA 102 (2005) 3395-3400
3. Carter T.A., Wodicka L.M., Shah N.P., Velasco A.M., Fabian M.A., Treiber D.K., Milanov Z.V., Atteridge C.E., Biggs III W.H., Edeen P.T., et al. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc. Natl. Acad. Sci. USA 102 (2005) 11011-11016
4. CCP4 (Collaborative Computational Project, Number 4). The CCP4 Suite: programs for protein crystallography. Acta Crystallogr. D Biol. Crystallogr. 50 (1994) 760-763
5. Cheetham G.M., Charlton P.A., Golec J.M., and Pollard J.R. Structural basis for potent inhibition of the Aurora kinases and a T315I multi-drug resistant mutant form of Abl kinase by VX-680. Cancer Lett. 251 (2007) 323-329
6. + cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment. Blood 105 (2005) 2093-2098
7. Daub H., Specht K., and Ullrich A. Strategies to overcome resistance to targeted protein kinase inhibitors. Nat. Rev. Drug Discov. 3 (2004) 1001-1010
8. Ditchfield C., Johnson V.L., Tighe A., Ellston R., Haworth C., Johnson T., Mortlock A., Keen N., and Taylor S.S. Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores. J. Cell Biol. 161 (2003) 267-280
9. Emsley P., and Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60 (2004) 2126-2132
10. Girdler F., Gascoigne K.E., Eyers P.A., Hartmuth S., Crafter C., Foote K.M., Keen N.J., and Taylor S.S. Validating Aurora B as an anti-cancer drug target. J. Cell Sci. 119 (2006) 3664-3675
11. Glaab W.E., and Tindall K.R. Mutation rate at the hprt locus in human cancer cell lines with specific mismatch repair-gene defects. Carcinogenesis 18 (1997) 1-8
12. Gorre M.E., Mohammed M., Ellwood K., Hsu N., Paquette R., Rao P.N., and Sawyers C.L. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293 (2001) 876-880
13. Harrington E.A., Bebbington D., Moore J., Rasmussen R.K., Ajose-Adeogun A.O., Nakayama T., Graham J.A., Demur C., Hercend T., Diu-Hercend A., et al. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat. Med. 10 (2004) 262-267
14. Hauf S., Cole R.W., LaTerra S., Zimmer C., Schnapp G., Walter R., Heckel A., van Meel J., Rieder C.L., and Peters J.M. The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore-microtubule attachment and in maintaining the spindle assembly checkpoint. J. Cell Biol. 161 (2003) 281-294
15. Kantarjian H., Giles F., Wunderle L., Bhalla K., O'Brien S., Wassmann B., Tanaka C., Manley P., Rae P., Mietlowski W., et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N. Engl. J. Med. 354 (2006) 2542-2551
16. Lipp J.J., Hirota T., Poser I., and Peters J.M. Aurora B controls the association of condensin I but not condensin II with mitotic chromosomes. J. Cell Sci. 120 (2007) 1245-1255
17. Manfredi M.G., Ecsedy J.A., Meetze K.A., Balani S.K., Burenkova O., Chen W., Galvin K.M., Hoar K.M., Huck J.J., LeRoy P.J., et al. Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase. Proc. Natl. Acad. Sci. USA 104 (2007) 4106-4111
18. Manning G., Whyte D.B., Martinez R., Hunter T., and Sudarsanam S. The protein kinase complement of the human genome. Science 298 (2002) 1912-1934
19. Melo J.V., and Chuah C. Resistance to imatinib mesylate in chronic myeloid leukaemia. Cancer Lett. 249 (2007) 121-132
20. Murshudov G.N., Vagin A.A., and Dodson E.J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. D Biol. Crystallogr. 53 (1997) 240-255
21. Otwinowski Z., and Minor W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276 (1997) 307-326
22. Roche-Lestienne C., Soenen-Cornu V., Grardel-Duflos N., Lai J.L., Philippe N., Facon T., Fenaux P., and Preudhomme C. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 100 (2002) 1014-1018
23. Ruchaud S., Carmena M., and Earnshaw W.C. Chromosomal passengers: conducting cell division. Nat. Rev. Mol. Cell Biol. 8 (2007) 798-812
24. Sawyers C.L. Calculated resistance in cancer. Nat. Med. 11 (2005) 824-825
25. Sessa F., Mapelli M., Ciferri C., Tarricone C., Areces L.B., Schneider T.R., Stukenberg P.T., and Musacchio A. Mechanism of Aurora B activation by INCENP and inhibition by hesperadin. Mol. Cell 18 (2005) 379-391
26. Shah N.P., Nicoll J.M., Nagar B., Gorre M.E., Paquette R.L., Kuriyan J., and Sawyers C.L. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2 (2002) 117-125
27. Shah N.P., Tran C., Lee F.Y., Chen P., Norris D., and Sawyers C.L. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305 (2004) 399-401
28. Shah N.P., Skaggs B.J., Branford S., Hughes T.P., Nicoll J.M., Paquette R.L., and Sawyers C.L. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J. Clin. Invest. 117 (2007) 2562-2569
29. Sherbenou D.W., and Druker B.J. Applying the discovery of the Philadelphia chromosome. J. Clin. Invest. 117 (2007) 2067-2074
30. Soncini C., Carpinelli P., Gianellini L., Fancelli D., Vianello P., Rusconi L., Storici P., Zugnoni P., Pesenti E., Croci V., et al. PHA-680632, a novel Aurora kinase inhibitor with potent antitumoral activity. Clin. Cancer Res. 12 (2006) 4080-4089
31. Talpaz M., Shah N.P., Kantarjian H., Donato N., Nicoll J., Paquette R., Cortes J., O'Brien S., Nicaise C., Bleickardt E., et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N. Engl. J. Med. 354 (2006) 2531-2541
32. Taylor S., and Peters J.M. Polo and Aurora kinases-lessons derived from chemical biology. Curr. Opin. Cell Biol. 20 (2008) 77-84
33. Teraishi F., Wu S., Zhang L., Guo W., Davis J.J., Dong F., and Fang B. Identification of a novel synthetic thiazolidin compound capable of inducing c-Jun NH2-terminal kinase-dependent apoptosis in human colon cancer cells. Cancer Res. 65 (2005) 6380-6387
34. Tighe A., Johnson V.L., and Taylor S.S. Truncating APC mutations have dominant effects on proliferation, spindle checkpoint control, survival and chromosome stability. J. Cell Sci. 117 (2004) 6339-6353
35. Tyler R.K., Shpiro N., Marquez R., and Eyers P.A. VX-680 inhibits Aurora A and Aurora B kinase activity in human cells. Cell Cycle 6 (2007) 2846-2854
36. Vagin A., and Teplyakov A. MOLREP: an automated program for molecular replacement. J. Appl. Cryst. 30 (1997) 1022-1025
37. Weisberg E., Manley P.W., Breitenstein W., Bruggen J., Cowan-Jacob S.W., Ray A., Huntly B., Fabbro D., Fendrich G., Hall-Meyers E., et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 7 (2005) 129-141
38. Weisberg E., Manley P.W., Cowan-Jacob S.W., Hochhaus A., and Griffin J.D. Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat. Rev. Cancer 7 (2007) 345-356
39. Weiss W.A., Taylor S.S., and Shokat K.M. Recognizing and exploiting differences between RNAi and small-molecule inhibitors. Nat. Chem. Biol. 3 (2007) 739-744
40. Wilkinson R.W., Odedra R., Heaton S.P., Wedge S.R., Keen N.J., Crafter C., Foster J.R., Brady M.C., Bigley A., Brown E., et al. AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis. Clin. Cancer Res. 13 (2007) 3682-3688